CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have disclosed a combined beneficial ownership of 5,449,161 shares, or 5.6%, of CRISPR Therapeutics AG (CRSP) Common Stock as of June 30, 2026. Orbis holds the vast majority of these shares with sole voting and dispositive power, while Allan Gray Australia holds a smaller portion, also with sole voting and dispositive power. Both entities disclaim being part of a group for beneficial ownership purposes.
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with rising revenue and a narrower net loss, offering some relief regarding its cash burn. While these results strengthen the company's position, the market views them as helpful but not thesis-changing, as the core investment narrative still hinges on the eventual success of its gene-editing pipeline and commercial uptake. Investors should consider the impact of sustained losses on future funding needs and weigh various fair value estimates.
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (CRSP) reported improved Q2 2026 results, with revenue rising to US$10.18 million and net loss narrowing to US$91.15 million. While these results slightly ease concerns about cash burn and progress, the investment narrative still hinges on the success of its gene-editing pipeline, clinical readouts, and commercial uptake. The market views these improvements as helpful but not yet thesis-changing, with fair value estimates varying significantly among investors.
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% in the first quarter, selling 113,815 shares and retaining 983,072 shares valued at $46.765 million. Institutional investors collectively own 69.2% of the company, which reported a quarterly loss of $0.94 per share on $10.18 million in revenue, with analysts projecting a full-year loss of $4.53 per share. Despite ongoing losses, analysts maintain a "Moderate Buy" consensus rating with an average price target of $68.06.
CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise
CRISPR Therapeutics (CRSP) stock has seen a significant decline over the past five years but now appears to be fairly valued. Despite promising allogeneic CAR-T programs, its Price-to-Book ratio is in line with the biotech industry average, suggesting investors acknowledge its potential without pricing in overly optimistic outcomes. The company's future valuation will largely depend on its ability to translate research into viable products while maintaining its financial stability.
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (CRSP) recently reported improved Q2 2026 results with rising revenue of US$10.18 million and a narrower net loss of US$91.15 million, easing immediate cash burn concerns. While these results strengthen the company's position for future clinical and regulatory milestones, they haven't fundamentally altered the market's investment thesis, which remains focused on the long-term success of its gene-editing pipeline. Investors should consider diverse fair value estimates and the impact of sustained losses on future funding.
CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares
CRISPR Therapeutics AG's Chief Financial Officer, Prasad Raju, reported a bona fide gift of 750 Common Shares on August 7, 2026. This transaction is classified as a disposition, and following the gift, Raju directly holds 14,815 Common Shares. The Form 4 filing indicates the transfer was a gift with a reported price of $0.00 per share and was not made under a Rule 10b5-1 plan.
CRISPR Therapeutics AG (CRSP) Stock Forecasts
This article provides an analyst report from Morningstar on CRISPR Therapeutics AG (CRSP), noting that its gene-editing therapy Casgevy is gaining traction despite initial commercial hurdles. The report highlights the company's focus on CRISPR/Cas9-based therapeutics. It also includes various market data and related analyst reports for other companies.
CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 613.5% in the first quarter, now owning 47,989 shares valued at $2.28 million. Institutional investors hold 69.2% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $68.06. The company reported a quarterly loss of $0.94 per share on $10.18 million in revenue, while continuing development of its CRISPR/Cas9 gene-editing therapies.
CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value?
CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with higher revenue and a reduced net loss, leading to a short-term stock rebound. Despite mixed long-term performance, a discounted cash flow (DCF) model suggests the stock is significantly undervalued at $53.52 compared to a fair value of $218.96. However, its Price-to-Book ratio is higher than the industry average, presenting a mixed valuation picture for investors.
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen
Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from a "Sell" to a "Hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average target price of $68.06. Despite a recent 3.6% increase in share price, the company reported a quarterly loss of $0.94 per share. Institutional ownership is high at 69.2%, though one insider sold shares to cover tax obligations.
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
RBC Capital has maintained its Hold rating on Crispr Therapeutics AG (CRSP) with a price target of $50.00. This comes as Crispr Therapeutics reported a quarterly revenue of $10.18 million and a GAAP net loss of $91.15 million in its latest earnings release. The company has an analyst consensus of Moderate Buy with a higher price target consensus of $72.64, indicating a potential 46.54% upside.
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Goldman Sachs has reiterated a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $55.00. This follows similar Hold ratings from other analysts like Wells Fargo, though H.C. Wainwright maintained a Buy rating. The company recently reported quarterly revenue of $10.18 million and a GAAP net loss of $91.15 million.
Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP
Brave Asset Management Inc. significantly reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 67.7% in the second quarter, now owning 11,234 shares worth $613,000. This comes amidst mixed activity from other institutional investors and varying analyst ratings for the gene-editing company. CRISPR Therapeutics recently posted earnings of ($0.94) EPS and $10.18 million in revenue for the quarter, with analysts expecting a negative EPS for the current year.
Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP
Dimensional Fund Advisors LP significantly reduced its stake in CRISPR Therapeutics AG by 45.5% in the first quarter, selling 412,889 shares. Following the sale, the firm now owns 494,218 shares valued at $23.49 million. The article also covers recent analyst ratings, insider trading activity, and CRISPR Therapeutics' financial performance and pipeline developments.
Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next
CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following its second-quarter 2026 results, which included an increase in revenue to US$10.18 million, a narrowed net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo trials in cardiovascular, autoimmune, and oncology indications, strengthening its investment narrative despite ongoing losses and funding risks. While the stock has seen limited movement over three years, these updates provide new near-term catalysts, though core uncertainties regarding long-term adoption and clinical success remain.
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10m, significantly beating estimates, and a smaller-than-expected statutory loss. Following these results, analysts have substantially increased revenue forecasts for 2026 to US$54.4m and reduced expected losses, anticipating significant growth. Despite these upgrades, the consensus price target of US$87.17 remains unchanged, although individual analyst targets show wide divergence.
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10 million, significantly beating estimates by 37%, and a smaller-than-expected loss of US$0.94 per share. Following these results, analysts have raised their revenue forecasts for 2026 to US$54.4 million and slightly reduced loss per share estimates, indicating a bullish outlook. Despite these upgrades, the consensus price target remains unchanged at US$87.17, although individual analyst targets show a wide divergence.
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and a GAAP net
Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next
CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following positive Q2 2026 results, which included an increase in revenue, a shrinking net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo trials across cardiovascular, autoimmune, and oncology indications, strengthening its gene-editing pipeline. Despite these positive developments, the company remains loss-making, and investors hold varied opinions on its fair value, highlighting ongoing uncertainties regarding commercial adoption and clinical success.
CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside
The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among 23 analysts remains a "Buy," with 13 Buys, 10 Holds, and no Sells.
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration revenue from Casgevy sales. Casgevy, developed with Vertex Pharmaceuticals, saw significant sales growth and expanded regulatory approvals, while CRISPR Therapeutics maintained a robust cash position and continues to advance a diverse clinical pipeline with multiple updates anticipated in the second half of 2026.
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share in Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. Total revenues reached $10.2 million, also exceeding the $7 million estimate, driven by strong collaboration revenue. The company's Casgevy gene therapy, developed with Vertex Pharmaceuticals, is showing robust sales momentum, while CRISPR Therapeutics continues to advance multiple candidates in its clinical pipeline.
FDA Approval Expands CASGEVY to Children as Young as 2
CRISPR Therapeutics reported strong Q2 2026 financial results, with CASGEVY revenue reaching $76 million, a 151% year-over-year increase. A significant highlight was the FDA's approval of CASGEVY for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, potentially making 5,500 more patients eligible. The company also advanced several other clinical programs and maintained a robust cash position of $2.36 billion.
Crispr Therapeut (CRSP) Stock News & Updates
This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor conferences and previously reported a convertible senior notes offering.
Crispr Therapeutics earnings beat by $0.26, revenue topped estimates
Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses Crispr Therapeutics' financial health as "fair performance."
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS
CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose 3.3% to $49.57, although they remain below their 52-week high, and analysts maintain a "Moderate Buy" consensus with a target price of $67.78.
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M
CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent inclusion in several Russell benchmarks and upcoming conference presentations.
CRISPR Therapeutics reports $91.2 million second quarter net loss
CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 million in revenue, demonstrating strong quarter-over-quarter and year-over-year growth. Insider trading activity showed 13 sales and no purchases of CRSP stock by executives over the past six months, and hedge funds exhibited mixed activity, with some major institutions adding and others reducing their positions.
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
CRISPR Therapeutics reported strong execution across its portfolio in Q2 2026, highlighted by continued momentum for CASGEVY with FDA approval for children as young as 2 and expansion of its in vivo pipeline. The company initiated Phase 1 trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. Financially, CRISPR Therapeutics reported CASGEVY revenue of $76 million and a net loss of $91.2 million for the quarter.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share
CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year increase, and a strong cash position of $2.36 billion. Despite these positive indicators, the significant net loss and low GuruFocus GF Score of 31/100, combined with insider selling, highlight ongoing challenges and caution for investors.
CRISPR Therapeutics (CRSP) Expected to Release Earnings on Monday
CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though Wall Street maintains a "Moderate Buy" consensus rating with a target price of $67.78. Institutional investors hold a significant portion of the stock, while recent insider transactions show a sale by Naimish Patel to cover tax obligations.
CRSP Stock Price and Chart — NASDAQ:CRSP
This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, future outlook, and financial health. The page further includes technical analysis summaries, analyst ratings, and a list of ETFs holding CRSP stock, alongside frequently asked questions about its performance and financials.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK)
This article discusses mixed analyst opinions on two healthcare stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK). Crispr Therapeutics received a "Moderate Buy" consensus with an attractive price target upside, while GlaxoSmithKline holds a "Hold" consensus with a modest upside. The report highlights specific analyst ratings and price targets for each company.
CRISPR Therapeutics AG (CRSP) Financial Health: Profitability & Balance Sheet Analysis
CRISPR Therapeutics AG (CRSP) has a weak financial status with a current financial score of 6.45, ranking 242 out of 384 in its industry. Despite a 68.55% year-over-year revenue increase to $1.46M and a 9.61% net profit increase, its operating efficiency is low. The article notes that relevant data for several financial health metrics have not yet been disclosed by the company.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
CRISPR Therapeutics AG (CRSP) saw a 1.68% increase in its stock price, outperforming the S&P 500's daily gain, despite a 14.35% decrease over the last month. Analysts anticipate positive year-over-year growth in upcoming earnings, with expected earnings of -$1.1 per share and revenue of $7.42 million. The company currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
Morgan Stanley analyst Terence Flynn recently raised the price target for CRISPR Therapeutics (NASDAQ: CRSP) to $60 from $33, implying a 26% upside, and upgraded the rating to "hold." Despite a challenging year for its stock, CRISPR Therapeutics has several catalysts ahead, including the recent label expansion for its gene-editing medicine Casgevy and upcoming data readouts for pipeline candidates CTX310 and CTX611. While clinical failures pose a risk, the company's deep pipeline and proven ability to secure drug approval make it an attractive prospect.
EverSource Wealth Advisors LLC Has $4.27 Million Stock Position in CRISPR Therapeutics AG $CRSP
EverSource Wealth Advisors LLC significantly increased its stake in CRISPR Therapeutics (CRSP) by 56.1% in the first quarter, now holding 89,683 shares valued at approximately $4.27 million. Institutional investors and hedge funds own a substantial 69.2% of the company. Despite the stock opening well below its 52-week high and the company remaining unprofitable, analysts largely maintain a "Moderate Buy" rating with an average price target of $67.78.
How Crispr Therapeutics Ag (CRSP) Affects Rotational Strategy Timing
This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP) using AI models to provide trading strategies. It highlights weak sentiment across all horizons, suggesting a short bias, and details position, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss levels. The analysis emphasizes risk-reward ratios and multi-timeframe signal analysis for traders.
CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh Revenue Breakdown – SET:CRSP03
CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh (CRSP03) generated 110.73 million THB in revenue last year, primarily from its Genome-editing Technology segment, a decrease from 1.28 billion THB the previous year. The majority of this revenue came from Switzerland and the United States.
Price to earnings forward of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03
This article focuses on the "Price to earnings forward" metric for CRISPR Therapeutics AG Shs Thailand Depositary Receipts, traded on the Stock Exchange of Thailand under the symbol CRSP03. It's a financial data point from TradingView, indicating a specific period, value, and change for this metric. The article primarily consists of navigation and boilerplate financial disclosure information from TradingView and its data providers.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has garnered investor attention, appearing on Zacks.com's list of most searched stocks. Despite a recent share decline, the article highlights the importance of earnings estimate revisions, revenue growth potential, and valuation in assessing the stock's future. CRISPR Therapeutics currently holds a Zacks Rank #3 (Hold), indicating it may perform in line with the broader market.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CRISPR Therapeutics AG (CRSP) is projected to report a significant year-over-year increase in earnings and revenue for the quarter ended June 2026, with an expected loss of $1.10 per share and revenues of $7.42 million. The company has a positive Earnings ESP of +1.94% and a Zacks Rank #3, suggesting a strong likelihood of beating consensus EPS estimates. Investors should also consider other factors beyond just earnings beats when making investment decisions.
BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics
BlackRock, Inc. has filed an amended ownership report, disclosing a beneficial ownership of 7,987,262 shares, or an 8.3% stake, in CRISPR Therapeutics AG common stock. The filing, a SCHEDULE 13G/A, indicates that BlackRock holds sole voting power over 7,841,979 shares and sole dispositive power over all 7,987,262 shares, with no shared powers. While various clients have rights to dividends or sale proceeds, no single client holds more than five percent of CRISPR Therapeutics AG's outstanding shares.
CRISPR Therapeutics AG (CRSP) Cash Flow
This article provides a detailed cash flow statement for CRISPR Therapeutics AG (CRSP), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, net income from continuing operations, capital expenditures, and free cash flow for various fiscal periods. The document aims to help users evaluate the company's financial soundness and stability by examining its cash generation and usage.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CRISPR Therapeutics AG (CRSP) is anticipated to exceed earnings estimates for the quarter ending June 2026, with an expected year-over-year increase in earnings and a significant rise in revenues. The company's positive Earnings ESP of +1.94% combined with a Zacks Rank #3 suggests a high probability of an earnings beat. Investors are advised to consider other factors beyond just earnings surprises when making investment decisions.
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for CRISPR Therapeutics AG (CRSP), noting its current earnings forecast score and industry ranking. It presents analyst ratings, target prices, and a peer comparison, along with expected EPS and revenue figures. The consensus among analysts is a "Buy" recommendation for CRSP stock, though investors are advised to conduct their own analysis.
CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T
CRISPR Therapeutics (CRSP) has initiated Phase 1 clinical trials for its allogeneic CAR T candidate CTX112, targeting lymphoma and autoimmune diseases. This move expands the company's focus beyond gene editing, aiming to address critical issues of cost, manufacturing complexity, and access associated with current individualized CAR T therapies. While the company faces competitive pressure from established players, CTX112 offers a new potential revenue stream and positions CRISPR Therapeutics in a rapidly evolving and significant market segment.
Affinity Asset Advisors LLC Buys Shares of 150,000 CRISPR Therapeutics AG $CRSP
Affinity Asset Advisors LLC has acquired a new position in CRISPR Therapeutics AG, purchasing 150,000 shares valued at approximately $7.14 million during the first quarter. This addition contributes to the significant institutional ownership of CRISPR Therapeutics, with hedge funds and other investors holding about 69.2% of the company's stock. Despite a recent earnings report showing a loss of $1.28 per share and the stock trading near its 52-week low, analysts maintain a "Moderate Buy" consensus rating with a target price of $67.78.
CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990
CRISPR Therapeutics AG (CRSP) is a Switzerland-based gene editing company with high growth potential, though its stock performance has been weak recently. The company's valuation is considered fair, and institutional ownership is very high. Analysts have rated it as a "Buy" with a significant upside, despite its current sideways trading pattern.
